Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2015

01-04-2015 | Research Article

Drug-related problems in institutionalized, polymedicated elderly patients: opportunities for pharmacist intervention

Authors: Cristina Silva, Célia Ramalho, Isabel Luz, Joaquim Monteiro, Paula Fresco

Published in: International Journal of Clinical Pharmacy | Issue 2/2015

Login to get access

Abstract

Background An aging population and the increasing prevalence of chronic diseases have led to the increased use of medicines. Portugal is one of the European countries where more medicines are consumed and the associated expense is higher. Medicines are associated with enormous health benefits but also with the potential to cause illness and death. A drug related problem (DRP) is an “an event or circumstance involving drug therapy that actually or potentially interferes with desired health outcomes”. In the U.S., they represent the 4th–6th leading cause of death and have an estimated cost of 130 billion dollars. Moreover, many of these DRP can be avoided. Elderly are at increased risk of DRP due to multiple factors: pluripathology and consequent polypharmacy, complex dosing regimens, pharmacokinetic/pharmacodynamic and functional/cognitive changes. Therefore, this population would be the one who would benefit most from the prevention, detection and control of DRP. The role of the pharmacist as an integral element of health care has been recognized by various international and European organizations. Providing pharmaceutical care as a patient-centered activity, focusing on their needs related to pharmacotherapy, contributes to guarantee that drug expenditure is a good investment, with benefits that outweigh potential risks. Objective To evaluate the need for pharmaceutical care implementation in institutionalized, polymedicated elderly. Methods Descriptive observational cross-sectional study carried out in six Portuguese nursing homes, selected by convenience, in November–December 2013. Each institution selected up to six patients, according to the following inclusion criteria: age ≥65 years, number of medications ≥5 and ability to respond to an interview. All participants signed an informed consent form. Pharmacists carried out a structured interview with each patient and consulted patient medical records to gather demographic data and information on health problems and medications used. To identify DRP, official drug information sources were consulted, and the STOPP and START tool was used. The ATC, the ICD-10 and the PCNE Classification V 6.2 classification systems were used for medicines, health problems and DRP classifications, respectively. For each medicine used, the cheapest equivalent available was also identified. Results The sample included 31 elderly (64.52 % female, mean age 81.65 ± 6.86). On average, subjects presented a mean of 7.94 ± 2.76 health problems with diseases of the circulatory system being the most common. The sample used a median of ten medicines per patient. Those medicines working in the cardiovascular, nervous and digestive systems were the most frequently used (29.75, 29.43 and 19.30 %, respectively). A total of 484 DRP (median: 15 DRP/patient) was found. The most common DRP were Adverse Drug Event, non-allergic (49.51 %), Drug treatment more costly than necessary (19.11 %), Effect of drug treatment not optimal (14.82 %) and Unnecessary drug treatment (6.16 %). The most cost-effective proposal, would lead to a saving of € 3,950/year in the studied sample. Conclusion These results reinforce the need for the implementation of pharmaceutical care services to institutionalized elderly, necessary to improve medicines efficacy and safety, better clinical outcomes and cost reduction.
Literature
1.
go back to reference Campos AC. Health reforms—the conductor wire. Edições Almedina. 2008. ISBN:9789724036045. Campos AC. Health reforms—the conductor wire. Edições Almedina. 2008. ISBN:9789724036045.
2.
go back to reference Hafner JW Jr, Belknap SM, Squillante MD, Bucheit KA. Adverse drug events in emergency department patients. Ann Emerg Med. 2002;39(3):258–67.CrossRefPubMed Hafner JW Jr, Belknap SM, Squillante MD, Bucheit KA. Adverse drug events in emergency department patients. Ann Emerg Med. 2002;39(3):258–67.CrossRefPubMed
3.
go back to reference Baena MI, et al. Medicine-related problems resulting in emergency. Eur J Clin Pharmacol. 2006;62:387–93.CrossRefPubMed Baena MI, et al. Medicine-related problems resulting in emergency. Eur J Clin Pharmacol. 2006;62:387–93.CrossRefPubMed
4.
go back to reference Queneau P, et al. Emergency department visits caused by adverse drug events. Results of a French survey. Drug Saf. 2007;30(1):81–8.CrossRefPubMed Queneau P, et al. Emergency department visits caused by adverse drug events. Results of a French survey. Drug Saf. 2007;30(1):81–8.CrossRefPubMed
5.
go back to reference Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858–66.CrossRefPubMed Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858–66.CrossRefPubMed
6.
go back to reference World Health Organization, Department of Medicines Policy and Standards; International Pharmaceutical Federation. Developing pharmacy practice—a focus on patient care. In: Wiedenmayer K, Summers RS, Mackie CA, Gous AG, Everard M, Tromp D, editors. Handbook—2006 Edition. The Netherlands: World Health Organization; 2006. World Health Organization, Department of Medicines Policy and Standards; International Pharmaceutical Federation. Developing pharmacy practice—a focus on patient care. In: Wiedenmayer K, Summers RS, Mackie CA, Gous AG, Everard M, Tromp D, editors. Handbook—2006 Edition. The Netherlands: World Health Organization; 2006.
7.
go back to reference McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36(9):1331–6.CrossRefPubMed McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36(9):1331–6.CrossRefPubMed
8.
go back to reference Beijer HJM, Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta analysis of observational studies. Pharm World Sci. 2002;24(2):46–54.CrossRefPubMed Beijer HJM, Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta analysis of observational studies. Pharm World Sci. 2002;24(2):46–54.CrossRefPubMed
9.
go back to reference Guerreiro MP, Cantrill JM, Pisco L, Martins AP. Considerations on preventable drug related morbidity in primary care part I—impact of preventable drug-related morbidity. Rev Port Clin Geral. 2005;21:269–79. Guerreiro MP, Cantrill JM, Pisco L, Martins AP. Considerations on preventable drug related morbidity in primary care part I—impact of preventable drug-related morbidity. Rev Port Clin Geral. 2005;21:269–79.
14.
go back to reference Veehof LJG, Stewart RE, Haaijer-Ruskamp FM, Meyboom-de Jong B. The development of polypharmacy. A longitudinal study. Fam Pract. 2000;17:261–7.CrossRefPubMed Veehof LJG, Stewart RE, Haaijer-Ruskamp FM, Meyboom-de Jong B. The development of polypharmacy. A longitudinal study. Fam Pract. 2000;17:261–7.CrossRefPubMed
15.
go back to reference Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.CrossRefPubMedCentralPubMed Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.CrossRefPubMedCentralPubMed
16.
go back to reference Krska J, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing. 2001;30:205–11.CrossRefPubMed Krska J, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing. 2001;30:205–11.CrossRefPubMed
19.
go back to reference Carter BL, et al. A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens. 2008;10:260–71.CrossRef Carter BL, et al. A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens. 2008;10:260–71.CrossRef
20.
go back to reference Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (screening tool of older person’s prescriptions) and START (screening tool to alert doctors to right treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.CrossRefPubMed Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (screening tool of older person’s prescriptions) and START (screening tool to alert doctors to right treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.CrossRefPubMed
21.
go back to reference Verrue C, Petrovic M, Mehuys E, Boussery K, Somers A, Spinewine A, et al. Organization of the medication management process in Belgian nursing homes. JAMDA. 2011;12(4):308–11.PubMed Verrue C, Petrovic M, Mehuys E, Boussery K, Somers A, Spinewine A, et al. Organization of the medication management process in Belgian nursing homes. JAMDA. 2011;12(4):308–11.PubMed
22.
go back to reference Sergi G, De Rui M, Sarti S, Manzato E. Polypharmacy in the elderly: Can comprehensive geriatric assessment reduce inappropriate medication use? Drugs Aging. 2011;28(7):509–18.CrossRefPubMed Sergi G, De Rui M, Sarti S, Manzato E. Polypharmacy in the elderly: Can comprehensive geriatric assessment reduce inappropriate medication use? Drugs Aging. 2011;28(7):509–18.CrossRefPubMed
23.
go back to reference Mendes Z, Guedes S, Marques FB, Miranda A. A terapêutica e custos no idoso polimedicados. Farmácia Observatório. 2009;23:6–7. Mendes Z, Guedes S, Marques FB, Miranda A. A terapêutica e custos no idoso polimedicados. Farmácia Observatório. 2009;23:6–7.
24.
go back to reference Onder G, Liperoti R, Fialova D, Topinkova E, Tosato M, Danese P, et al. Polypharmacy in nursing home in Europe: results from the SHELTER study. J Gerontol A Biol Sci Med Sci. 2012;67(6):698–704.CrossRefPubMed Onder G, Liperoti R, Fialova D, Topinkova E, Tosato M, Danese P, et al. Polypharmacy in nursing home in Europe: results from the SHELTER study. J Gerontol A Biol Sci Med Sci. 2012;67(6):698–704.CrossRefPubMed
25.
go back to reference Dwyer LL, Han B, Woodwell DA, Rechtsteiner EA. Polypharmacy in nursing home residents in the United States: results of the 2004 national nursing home survey. Am J Geriatr Pharmacother. 2010;8(1):63–72.CrossRefPubMed Dwyer LL, Han B, Woodwell DA, Rechtsteiner EA. Polypharmacy in nursing home residents in the United States: results of the 2004 national nursing home survey. Am J Geriatr Pharmacother. 2010;8(1):63–72.CrossRefPubMed
26.
go back to reference Huang AR, Mallet L, Rochefort CM, Eguale T, Buckeridge DL, Tamblyn R. Medication-related falls in the elderly: causative factors and preventive strategies. Drugs Aging. 2012;29(5):359–76.CrossRefPubMed Huang AR, Mallet L, Rochefort CM, Eguale T, Buckeridge DL, Tamblyn R. Medication-related falls in the elderly: causative factors and preventive strategies. Drugs Aging. 2012;29(5):359–76.CrossRefPubMed
27.
go back to reference Hill KD, Wee R. Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. Drugs Aging. 2012;29(1):15–30.CrossRefPubMed Hill KD, Wee R. Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. Drugs Aging. 2012;29(1):15–30.CrossRefPubMed
28.
go back to reference de Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, et al. Prevalence and associations of the use of proton-pump inhibitors in nursing homes: a cross-sectional study. JAMDA. 2013;14(4):265–9.PubMed de Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, et al. Prevalence and associations of the use of proton-pump inhibitors in nursing homes: a cross-sectional study. JAMDA. 2013;14(4):265–9.PubMed
29.
go back to reference Gallagher P, Barry P, O’Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther. 2007;32(2):113–21.CrossRefPubMed Gallagher P, Barry P, O’Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther. 2007;32(2):113–21.CrossRefPubMed
30.
go back to reference Brulhart MI, Wermeille JP. Multidisciplinary medication review: evaluation of a pharmaceutical care model for nursing homes. Int J Clin Pharm. 2011;33:549–57.CrossRefPubMed Brulhart MI, Wermeille JP. Multidisciplinary medication review: evaluation of a pharmaceutical care model for nursing homes. Int J Clin Pharm. 2011;33:549–57.CrossRefPubMed
31.
go back to reference Bootman JL, Harrison DL, Cox E. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med. 1997;157(18):2089–96.CrossRefPubMed Bootman JL, Harrison DL, Cox E. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med. 1997;157(18):2089–96.CrossRefPubMed
Metadata
Title
Drug-related problems in institutionalized, polymedicated elderly patients: opportunities for pharmacist intervention
Authors
Cristina Silva
Célia Ramalho
Isabel Luz
Joaquim Monteiro
Paula Fresco
Publication date
01-04-2015
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 2/2015
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-014-0063-2

Other articles of this Issue 2/2015

International Journal of Clinical Pharmacy 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.